|
Market Closed -
OTC Markets
09:30:01 2025-07-17 EDT
|
5-day change | 1st Jan Change | ||
| 0.3000 USD | +20.00% |
|
-.--% | - |
| 09-16 | Nicox to present NCX 470 data at a conference |  |
| 09-11 | Chinese Regulator Accepts Nicox's Glaucoma Drug Application for Review | MT |
Company Valuation: Nicox SA
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 109.8 | 55.83 | 22.05 | 19.32 | 24.12 | 27.58 | - |
| Change | - | -49.18% | -60.51% | -12.36% | 24.81% | 14.38% | - |
| Enterprise Value (EV) | 89.38 | 53.61 | 31.68 | 19.32 | 24.12 | 27.58 | 27.58 |
| Change | - | -40.02% | -40.9% | -39.01% | 24.81% | 14.38% | 0% |
| P/E | -2.18x | -1.78x | -1.05x | -0.88x | -9.93x | -6.26x | 15.7x |
| PBR | 1.45x | 1.04x | - | - | - | - | - |
| PEG | - | 0x | 0x | 0x | 0.1x | -0.1x | -0x |
| Capitalization / Revenue | 15.2x | 17.1x | 5.25x | 2.46x | 1.44x | 9.19x | 2.76x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 9.19x | 2.76x |
| EV / EBITDA | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | -0x | -0x | 0x | -5.52x | 13.8x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -1.17 | -0.63 | -0.42 | -0.32 | -0.03 | -0.05 | 0.02 |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | 7.233 | 3.271 | 4.2 | 7.859 | 16.77 | 3 | 10 |
| EBITDA | -16.61 | -22.86 | -17.04 | - | - | - | - |
| EBIT 1 | -46.01 | -33.96 | -17.06 | -9.854 | 4.626 | -5 | 2 |
| Net income 1 | -43.76 | -27.76 | -20.88 | -22.39 | -2.413 | -5 | 2 |
| Net Debt | -20.46 | -2.216 | 9.636 | - | - | - | - |
| Reference price 2 | 2.5550 | 1.1200 | 0.4420 | 0.2810 | 0.2980 | 0.3130 | 0.3130 |
| Nbr of stocks (in thousands) | 42,991 | 49,845 | 49,882 | 68,764 | 80,926 | 88,131 | - |
| Announcement Date | 4/28/22 | 3/20/23 | 4/22/24 | 4/29/25 | 4/30/26 | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 32.87x | 11.93x | 24.1x | 0.6% | 1,032B | |
| 28.34x | 6.29x | 17.98x | 2.1% | 614B | |
| 37.73x | 7.89x | 16.32x | 2.6% | 471B | |
| 103.26x | 5.79x | 24.59x | 2.4% | 350B | |
| 19.01x | 4.63x | 11.48x | 2.86% | 337B | |
| 19.87x | 5.19x | 12.84x | 3.07% | 268B | |
| 20.52x | 4.22x | 12.02x | 2.1% | 246B | |
| 25.43x | 6.65x | 11.85x | 2.51% | 218B | |
| -43.62x | 6.37x | 24.89x | 2.28% | 179B | |
| Average | 27.04x | 6.55x | 17.34x | 2.28% | 412.76B | |
| Weighted average by Cap. | 32.24x | 7.67x | 18.71x | 1.95% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ALCOX Stock
- NICXF Stock
- Valuation Nicox SA
Select your edition
All financial news and data tailored to specific country editions
